시장보고서
상품코드
1267699

세계의 혈장 유래 치료(면역글로불린, 혈우병, 특수, 알부민) 시장 : 코로나19의 잠재적 영향을 고려한 분석 및 예측(2023-2027년)

Plasma Derived Therapies Market (Immunoglobulin, Hemophilia, Specialty, and Albumin): Insights & Forecast with Potential Impact of COVID-19 (2023-2027)

발행일: | 리서치사: Koncept Analytics | 페이지 정보: 영문 76 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 혈장 유래 치료 시장 규모는 2023년부터 2027년까지 7.20%의 CAGR로 성장하여 2027년에는 543억 5,000만 달러에 달할 것으로 예상됩니다. 노인 인구 증가, 유전성 질환의 유병률 증가, 알부민 수요 증가, 의약품에서 혈장 단백질 사용 급증, 면역 글로불린 사용 증가가 시장 성장을 촉진하고 있습니다.

이 보고서는 세계 혈장 유래 치료(Plasma Derived Therapies) 시장에 대해 조사했으며, 시장 분석, 경쟁 상황, 기업 프로필 등 종합적인 정보를 제공합니다.

목차

제1장 시장 개요

  • 혈장 유래 치료
    • 서론
  • 혈장 유래 치료 부문
    • 면역글로불린
    • 혈우병
    • 알부민
  • 혈장 유래 치료 제조 프로세스
  • 혈장 유래 치료 밸류체인
  • 환자에게의 혈장 유래 치료의 이점

제2장 COVID-19의 영향

  • 의료 시장에 대한 COVID-19의 영향
  • COVID-19의 혈장에 대한 영향
  • 혈장 채취에 대한 COVID-19의 영향
  • COVID-19 확산

제3장 세계 시장 분석

  • 세계의 혈장 유래 치료 시장 : 금액별
  • 세계의 혈장 유래 치료 시장 예측 : 금액별
  • 세계의 혈장 유래 치료 시장 : 부문별
    • 세계의 면역글로불린 혈장 유래 치료 시장 : 금액별
    • 세계의 면역글로불린 혈장 유래 치료 시장 예측 : 금액별
    • 세계의 면역글로불린 혈장 유래 치료 시장 : 부문별
    • 세계의 면역글로불린 혈장 유래 치료 시장 예측 : 부문별
    • 세계의 혈우병 혈장 유래 치료 시장 : 금액별
    • 세계의 혈우병 혈장 유래 치료 시장 예측 : 금액별
    • 세계의 혈우병 혈장 유래 치료 시장 예측 : 부문별
    • 세계의 혈우병 혈장 유래 치료 시장 예측 : 부문별
    • 세계의 특수 혈장 유래 치료 시장 : 금액별
    • 세계의 특수 혈장 유래 치료 시장 예측 : 금액별
    • 세계의 알부민 혈장 유래 치료 시장 : 금액별
    • 세계의 알부민 혈장 유래 치료 시장 예측 : 금액별
  • 세계의 혈장 유래 치료 시장 : 지역별

제4장 지역별 시장 분석

  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카/중동 및 아프리카

제5장 시장 역학

  • 촉진요인
  • 주요 동향과 개발
  • 과제

제6장 경쟁 구도

  • 세계 시장
    • 혈장 시장 점유율 - 주요 기업
    • 면역글로불린 시장 점유율 - 주요 기업
    • 알부민 시장 점유율 - 주요 기업
  • 미국 시장
    • 미국과 EU 수집 센터 주요 기업

제7장 기업 개요

  • CSL Limited
  • Grifols
  • Takeda Pharmaceutical Company
  • Octapharma AG
  • Kedrion
  • ADMA Biologics
LSH 23.05.11

The global plasma derived therapy market is anticipated to reach US$54.35 billion in 2027, growing at a CAGR of 7.20% during the period spanning 2023-2027. The growth in the market has been driven by factors like rising geriatric population, increasing prevalence of genetic disorders, government initiatives, rising demand for albumin, escalating use of plasma proteins in pharmaceuticals, increasing usage of immunoglobulin, surging autoimmune disorders. The market is expected to face certain challenges such as high cost and stringent regulations. To overcome these challenges, the market would witness some key trends like technological advancements, rising demand for health insurance, escalating use of therapeutic protein drugs, and increasing adoption of plasma therapy in neurology.

The global plasma derived therapy market can be segmented as follows: Immunoglobulin, Hemophilia, Specialty, and Albumin. Immunoglobulin held a larger share of the market in 2022. Due to the rising use in primary immunodeficiency and neurological applications, the immunoglobulins market is predicted to grow. For example, Grifols, S.A., a pharmaceutical and chemical company, launched HyperHEP B, a new formulation of immune globulin derived from human plasma for hepatitis B postexposure prophylaxis, in June 2022, propelling the industry forward.

The global plasma derived therapy market by region can be segmented into the following: North America, Europe, Asia Pacific, and LAMEA. North America held a larger share of the market in 2022. Growing use of immunoglobulins in various therapeutic domains, increased plasma collection (and the number of plasma collection facilities), and rising prevalence of respiratory disorders and alpha-1-antitrypsin deficiency are all driving market expansion (AATD).

Scope of the report:

  • The report provides a comprehensive analysis of the global plasma derived therapy market, segmented into Immunoglobulin, Hemophilia, Specialty, and Albumin.
  • The major regional markets North America, Europe, Asia Pacific, and LAMEA have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (ADMA Biologics, Kedrion, Grifols, Takeda Pharmaceutical Company, Octapharma, and CSL Limited) are also presented in detail.

Key Target Audience:

  • Plasma collection Centers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 Plasma-Derived Therapies
    • 1.1.1 Introduction
  • 1.2 Segments of Plasma Derived Therapies
    • 1.2.1 Immunoglobulin
    • 1.2.2 Hemophilia
    • 1.2.3 Albumin
  • 1.3 Plasma Derived Therapy Production Process
  • 1.4 Value Chain of Plasma Derived Therapy
  • 1.5 Advantages of Plasma Derived Therapy for Patients

2. Impact of COVID-19

  • 2.1 Impact of COVID-19 on HealthCare Market
  • 2.2 Impact of COVID-19 on Plasma
  • 2.3 Impact of COVID-19 on Plasma Collection
  • 2.4 Prevalence of COVID-19

3. Global Market Analysis

  • 3.1 Global Plasma Derived Therapy Market by Value
  • 3.2 Global Plasma Derived Therapy Market Forecast by Value
  • 3.3 Global Plasma Derived Therapy Market by Segments
    • 3.3.1 Global Immunoglobulin Plasma Derived Therapy Market by Value
    • 3.3.2 Global Immunoglobulin Plasma Derived Therapy Market Forecast by Value
    • 3.3.3 Global Immunoglobulin Plasma Derived Therapy Market by Segments
    • 3.3.4 Global Immunoglobulin Plasma Derived Therapy Market Forecast by Segments
    • 3.3.5 Global Hemophilia Plasma Derived Therapy Market by Value
    • 3.3.6 Global Hemophilia Plasma Derived Therapy Market Forecast by Value
    • 3.3.7 Global Hemophilia Plasma Derived Therapy Market Forecast by Segments
    • 3.3.8 Global Hemophilia Plasma Derived Therapy Market Forecast by Segments
    • 3.3.9 Global Specialty Plasma Derived Therapy Market by Value
    • 3.3.10 Global Specialty Plasma Derived Therapy Market Forecast by Value
    • 3.3.11 Global Albumin Plasma Derived Therapy Market by Value
    • 3.3.12 Global Albumin Plasma Derived Therapy Market Forecast by Value
  • 3.4 Global Plasma Derived Therapy Market by Region

4. Regional Market Analysis

  • 4.1 North America
    • 4.1.1 North America Plasma Derived Therapy Market Forecast by Value
    • 4.1.2 North America Plasma Derived Therapy Market by Region
    • 4.1.3 The US Plasma Derived Therapy Market Forecast by Value
  • 4.2 Europe
    • 4.2.1 Europe Plasma Derived Therapy Market Forecast by Value
  • 4.3 Asia Pacific
    • 4.3.1 Asia Pacific Plasma Derived Therapy Market Forecast by Value
  • 4.4 LAMEA
    • 4.4.1 LAMEA Plasma Derived Therapy Market Forecast by Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Rising Geriatric Population
    • 5.1.2 Increasing Prevalence of Genetic Disorders
    • 5.1.3 Government Initiatives
    • 5.1.4 Rising Demand for Albumin
    • 5.1.5 Escalating Use of Plasma Proteins in Pharmaceuticals
    • 5.1.6 Increasing Usage of Immunoglobulin
    • 5.1.7 Suring Autoimmune Disorders
  • 5.2 Key Trends and Developments
    • 5.2.1 Technological Advancements
    • 5.2.2 Rising Demand for Health Insurance
    • 5.2.3 Escalating Use of Therapeutic Protein Drugs
    • 5.2.4 Increasing Adoption of Plasma Therapy in Neurology
  • 5.3 Challenges
    • 5.3.1 High Cost
    • 5.3.2 Stringent Regulations

6. Competitive Landscape

  • 6.1 Global Market
    • 6.1.1 Plasma Market Share- Key Players
    • 6.1.2 Immunoglobulin Market Share- Key Players
    • 6.1.3 Albumin Market Share- Key Players
  • 6.2 The US and Europe Market
    • 6.2.1 The US and EU Collection Centers Key Players

7. Company Profiles

  • 7.1 CSL Limited
    • 7.1.1 Business Overview
  • 7.2 Grifols
    • 7.2.1 Business Overview
  • 7.3 Takeda Pharmaceutical Company
    • 7.3.1 Business Overview
  • 7.4 Octapharma AG
    • 7.4.1 Business Overview
  • 7.5 Kedrion
    • 7.5.1 Business Overview
  • 7.6 ADMA Biologics
    • 7.6.1 Business Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제